Iraq reports 19 Congo fever deaths already this year
Crimean-Congo haemorrhagic fever
already this year and urged farmers and abattoir workers to step up precautions when handling livestock.
A total of 123 cases have been recorded nationwide, health ministry spokesman Saif al-Badr said in a statement, adding that 36 of them were reported in the poor southern province of Dhi Qar, which is heavily dependent on livestock farming.
Congo fever is a viral disease which is transmitted to people either by tick bites or through contact with infected animal blood or tissues during or immediately after slaughter, according to the World Health Organization.
It has a fatality rate of between 10 and 40 percent, and most cases have been reported in the livestock industry.
A previous surge in infections in Iraq in 2022 saw at least 27 deaths, compared with just six cases for the two decades from 1989 to 2009.
The WHO attributed that flare-up to a rise in the tick population resulting from the failure to carry out pesticide spraying campaigns in 2020 and 2021.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
ICMR invites EoIs for tech transfer to commercialise malaria vaccine
The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoI) from eligible companies and manufacturers to undertake the transfer of technology for commercialisation of an indigenous recombinant multi-stage malaria vaccine candidate named AdFalciVax. The vaccine candidate, being developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), aims to prevent plasmodium falciparum, a parasite which causes severe and fatal malaria, in humans and minimise its community transmission. According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases, effectively accelerating its development and commercialisation. The agreement is proposed to be executed on a non-exclusive basis with single or multiple companies to enable wider outreach of the malaria vaccine for societal benefit and public health use. It added that the development may take at least seven years in four stages with each stage having a six-month buffer time. While ICMR would provide technical support through its team of experienced scientists in study planning and product development, the selected company would be responsible for obtaining all the regulatory approvals, starting from research and development (R&D) for product development to its commercialisation. The Council will also have no financial implications unless otherwise specified, however, its institutes would provide support and facilitation to conduct the R&D and clinical studies of new technology in India. The EoI adds that in case of transfer of technology, ICMR is the sole owner of the said technology, including any underlying Intellectual Properties and commercialisation rights. 'In case of collaboration between ICMR and the company for the joint development of the technology/product, the Background Intellectual Property (BGIP) shall always remain the sole and non-exclusive property of the party generating it,' the EoI said. As part of the agreement, the collaborating company will be required to share technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the medical research body said. According to the World Health Organisation's (WHO) World Malaria Report 2024, India contributes half of all estimated cases in the South East Asia Region, which in turn accounts for 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines, Mosquirix and R21/Matrix-M. While the former is manufactured by GlaxoSmithKline (GSK), the latter is manufactured by the Serum Institute of India (SII). Both vaccines are primarily for children in areas with moderate to high malaria transmission. 'Based on preclinical data, AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines,' an official in the know said. The pre-clinical validation of the vaccine candidate was conducted in collaboration with the Indian Council of Medical Research-National Institute of Malaria Research, other constituent institutes of ICMR, and the National Institute of Immunology in Delhi, an autonomous research institute of the Department of Biotechnology.
India Today
5 hours ago
- India Today
India becomes first nation to digitise traditional medicine with AI-powered library
The launch of the Traditional Knowledge Digital Library (TKDL) has made India the first country in the world to digitise (making all information available in the digital mode) its traditional medicine systems using Artificial Intelligence. This move is a turning point for how ancient health knowledge like Ayurveda and Unani can be protected, studied, and used in today's by WHO and supported by the Indian government, the effort shows how modern tools can bring new life to centuries-old digitisation of TKDL is a methodical effort to ensure that knowledge systems like Ayurveda, Unani, Siddha, Sowa-Rigpa, and Homoeopathy are protected from misuse, studied with precision and applied. The World Health Organisation (WHO), in a recent report, acknowledged the move as an important development in the global push to integrate traditional and modern KNOWLEDGE, PREVENTING EXPLOITATIONThe roots of India's traditional medicine lie in oral traditions, palm-leaf manuscripts, and classical texts that go back hundreds, if not thousands, of the absence of documentation, there have been many instances in the past where foreign companies patented herbal formulations and treatments that had long existed in Indian TKDL was conceived as a solution to that translating and digitising these traditional formulations in multiple languages and coding them into formats understandable to patent offices, the library provides evidence that such knowledge already exists in the public sets the new version of TKDL apart is its use of Artificial Intelligence (AI). The database now uses machine learning tools to organise complex information, track patterns, and find possible links between traditional remedies and modern DIRECTIONS WITH AI AND AYURVEDAAmong the newer developments highlighted by WHO is Ayurgenomics, an emerging field that merges genetic science with Ayurvedic principles of body types, or in India are working to personalise treatment methods by combining DNA data with ancient health models are also being used in pulse reading and tongue analysis, both long-standing diagnostic methods in Ayurveda, to assist in making clinical Government of India, through the Ministry of Ayush, has said the aim is not only to preserve heritage but to push forward into areas where tradition and technology can Minister Prataprao Jadhav, speaking on the occasion, noted that this is part of a larger vision to make Indian systems more accessible while contributing to global health Prime Minister Narendra Modi has often spoken of using 'AI for all,' and healthcare is one of the key areas where that promise is beginning to take TKDL offers a framework that other countries with strong traditional medicine cultures, such as China, South Korea, or Indonesia, may find useful.- Ends
The Hindu
a day ago
- The Hindu
Cy-TB test introduced by Kerala govt. for detecting and treating tuberculosis
The State health authorities in Kerala have introduced a new intradermal test called Cy-TB for detecting and treating tuberculosis (TB) infection following the prioritisation of latent TB infection treatment under the National TB Elimination Programme (NTEP). TB infection is different from active TB disease. A person with TB infection harbours the organism causing TB infection (Mycobacterium tuberculosis) in the body, having probably acquired it through contact with someone with active disease. But the organism remains dormant or inactive in the body and the person neither has any TB symptoms nor is he contagious. However, if left untreated, 5-10% of them will progress to developing active TB disease when the body's immune system weakens, allowing the TB bacteria to flare up. This could happen within weeks of acquiring the infection or maybe years, depending on the immune system and other factors determining immune regulation. Study A community-based cross-sectional study among adults in Thiruvananthapuram district in 2023 had reported that roughly one-fifth of the adult population in the district – 20.5% of adults – have tuberculosis infection. The study, 'Prevalence of Tuberculosis Infection among Adults of Thiruvananthapuram District of Kerala as Measured by Interferon Gamma Release Assay – A Cross-Sectional Study,' tested whole blood samples of 396 adults in Thiruvananthapuram for TB infection and found that the prevalence of TB infection increased with age, ranging from 11.5% in the 18-35 age group to 30.3% in the 58-years-plus age group. 'Our studies show that about 22% of the State's general population has acquired TB infection from the community. While they pose no immediate threat to the community, once they go into an immuno-compromised state, the bacteria will multiply and produce symptoms of active disease. Given the morbidity profile of Kerala – high prevalence of diabetes, chronic kidney disease, heavy alcohol use and a huge population on dialysis – it is important that we identify and treat these people to reduce the future burden of TB,' says Aparna Mohan, Government of India-WHO consultant for TB. Cy-TB is a third generation test approved by the Central TB Division. Blood test detection Since 2021, Kerala has been using the blood test Interferon Gamma Release Assay (IGRA) for detecting TB infection. However, this test required extensive laboratory support and it had a waiting period too. There were also systemic difficulties in rolling it out. Cy-TB is a highly specific, accurate and user-friendly skin test, wherein 0.1 ml dose of M. tuberculosis-specific antigens (ESAT-6 and CFP-10) are injected into the skin in the inner forearm. An induration (a raised area) of 5 mm or more which develops on the skin within 48-72 hours indicates TB infection (While a trained nurse can administer the injection, the person will have to return to the health centre for checking out the skin reaction.) If tested positive, active TB has to be ruled out before considering TB preventive therapy. TB preventive therapy is optional and not currently recommended for all those who are infected. Only high risk individuals recommended for preventive therapy under the NTEP alone need to take preventive therapy. Risk groups In Kerala, the identified risk groups include individuals on immunosuppressive therapy, those with silicosis (lung disease following the inhalation of silica dust), those on anti-TNF treatment, and those on dialysis and awaiting organ transplantation. Preventive therapy is also offered to health-care workers who test positive in the Cy-TB test. The preventive therapy is a short regimen with less number of drugs. This could be three-month weekly Isoniazid and Rifapentine (3HP) or six-months daily Isoniazid (6H). According to the State TB Division, Cy-TB will be offered in district TB centres, taluk hospitals, at the block level in some districts and in all dialysis centres too. The Health department also intends to use Cy-TB to test inmates in old age homes where pulmonary TB has been reported. The test is currently available in major private hospitals too.
